Without doubt, some of medicine’s greatest opportunities have never come to light because they were consigned to the darkened corners of history before we had the technology or techniques to fully investigate them. Combining cutting edge science and unparalleled experience, Paradigm Biopharma is uniquely qualified to identify and liberate the true potential of under-utilised drugs and molecules to meet some of the world’s most significant unmet needs
Experts in uncovering the real value of a molecule
Paradigm’s immediate commercial focus is the repurposing of Pentosan Polysulphate Sodium (PPS) for the treatment of Osteoarthritis (OA). This is a global unmet need and we have advanced to phase 3 trials in the space. Addressing all aspects of the disease: inflammation, pain and regeneration, PPS has genuine disease modifying potential.
In the presence of inflammation, the body can’t begin regenerating. We are targeting Osteoarthritis (OA) and other conditions with Pentosan Polysulfate Sodium (PPS) because it may address the complex biological responses to injury, infection or allergy which have short and long term components mediated by factors produced by immune cells.
6th January 2021
21st Decemeber 2020
There a pipeline of potential indications for the use of PPS
Alphaviruses, including Ross River virus (RRv) and Chikungunya (CHIKV) are mosquito-transmitted arthritogenic alphaviruses that cause epidemics of severe musculoskeletal disease.
*Simon, Fabrice et al. “Chikungunya Virus Infection.” Current Infectious Disease Reports 13.3 (2011): 218–228. PMC. Web. 10 Oct. 2016
OA is a condition with a significant unmet medical need. Opioid abuse resulting from mismanagement of pain is a major problem in the US and most western countries.
*National Institute of Health; Emerging drugs for osteoarthritis; Hunter DJ and Matthews G 16(3): 479–491; 2011 September
Mucopolysaccharidoses are lysosomal storage disorders characterised by accumulation of abnormal pathological glycosaminoglycans, cellular dysfunction and widespread inflammation, resulting in progressive cognitive and motor decline.
Chronic Heart Failure (CHF)
Occurs in about 1% of people aged 50-59, but becomes more common from 80+ where its occurrence rate is over 50%. Lifetime risk for developing heart failure is 1 in 5 among both men and women.